# A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

> **NCT00671788** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00671788
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2016-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671788, "A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00671788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*